BioSpace News Archive

Feb. 7, 2020 13:00 UTC OncoSec Announces that Nevada Court Denies Alpha Holdings’ Motion to Enjoin Special Meeting of Shareholders Court Rules in Favor of OncoSec – Special Meeting of Shareholders Will Proceed as Planned Today SAN DIEGO & PENNINGTON, N.J.--( BUSINESS WIRE )-- OncoSec Medical Incorporated (NASDAQ:ONCS) (the “Company” or “OncoSec”), a company developing late-stage intratumoral cancer immunotherapies, today commented on the February 6 ruling from the Dist

PAY DATE: Monday, February 24, 2020 EX DATE: Tuesday, February 25, 2020 MIRAMAR, Fla., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation ( www.generex.com ) (OTCQB:GNBT) (“Generex”) is pleased to announce the successful completion of the FINRA review process for the dividend. After an exhaustive and long review, FINRA has determined that the original August 30 record date is too long ago to adequately track all the pay due bills from stock being bought and sold by investors

With the increasing incidence of Alzheimer’s disease and dementia, affected families are all too often “stretched to the breaking point,” according to Kara Bonela, Vice President, Marketing, Alzheimer’s Los Angeles.

REHOVOT, Israel, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today released a letter to shareholders: Dear Shareholders, Thank you for continuing to support the Company as we embark on this effort to transform into a US-focused blood diagnostics company preparing to embark on a clinical utility study

As part of its expansion into human health, GreenLight Biosciences, Inc. is pleased to welcome the first members of its new Life Sciences Advisory Board.

CorMatrix®Cardiovascular, Inc. www.cormatrix.com, a leading developer of regenerative cardiovascular medical devices, today announced receiving FDA approval to expand and enroll 20 additional patients in the adult arm, including up to 4 additional cardiac surgery research and investigative centers, for its early feasibility IDE study of the Cor® TRICUSPID ECM® valve* for pediatric and adult patients.

Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity, traceability solutions, nucleic acid-based biotherapeutic development, and liquid biopsies for cancer diagnostics, announced today and in a late-day Investor Call yesterday, that it has expanded its existing Joint Development Agreement (JDA) with Takis Biotech

eHealth, Inc. (Nasdaq: EHTH), a leading private online health insurance exchange in the United States, announced today that the company plans to release fourth quarter and fiscal year 2019 financial results on February 20, 2020.

Genome editing is a groundbreaking technology used to introduce intentional genomic alterations in animals and has the potential to improve human and animal health, animal well-being and to enhance food production and quality. It is paramount, however, that as we move forward, we maintain standards of safety and effectiveness.

Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Phillips has decided to retire from his role as the company’s Senior Vice President of Research and Development as of April 1, 2020.